Serum autoantibodies of tau and alpha synuclein proteins as potential Biomarkers for diagnosis of Alzheimer’s and Parkinson’s Diseases

Abstract

D ementia of Alzheimer’s type is the most common neurodegenerative disease that primarily affects the memory. It is globally recognized as the most common form of dementia. Pathological accumulation of tau aggregates is classically found in the brains of the patients with dementia of Alzheimer’s type, what is called tauopathies. The mechanisms by which tau protein becomes a nonfunctional entity are in debate. In addition to phosphorylation, tau also undergoes other post-translational modifications, such as glycosylation, nitration, truncation, acetylation, sumoylation, ubiquitination and polyamination, all of which affect tau phosphorylation and/or aggregation. Parkinson disease (PD) belongs to a group of conditions called involuntary movement disorders. It is the second most common adult-onset neurodegenerative disabling disease after dementia of Alzheimer’s type. Biomarker is a characteristic that can be objectively measured and evaluated as an indicator of a physiological as well as a pathological process or pharmacological response to a therapeutic intervention”